Creo Medical Group PLC First clinical use of new Creo GI product (9927H)

TIDMCREO

RNS Number : 9927H

Creo Medical Group PLC

09 December 2020

Creo Medical Group plc

("Creo" or the "Company")

First clinical use of new Creo GI product

   MicroBlate(TM)   Fine device used for successful pancreatic tumour ablation 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces the first in-man clinical use of its MicroBlate(TM) Fine device, believed to be the world's smallest fine needle microwave ablation device available for clinical practice. The device was used to successfully ablate pancreatic tumour tissue under Endoscopic Ultrasound guidance, without any procedural complications.

The MicroBlate(TM) Fine device has the same dimensions as a routine biopsy needle, greatly reducing the risk of procedural bleeding and allowing very accurate targeting of microwave ablation in highly perfused organs such as the liver, kidney, lung as well as the pancreas.

Craig Gulliford, Chief Executive Officer of Creo, commented: " We are very pleased with the first in-man clinical use of the MicroBlate(TM) Fine device, bringing fine needle microwave ablation into clinical practice for the first time and in particular, as in this case, in the hands of GI physicians. This is a fantastic milestone for the Company and the entire Creo team. We look forward to further clinical firsts and regulatory announcements related to our increasing suite of GI devices. More importantly, however, this milestone has helped improve the outcome and made a difference to the life of another of our patients. "

This announcement contains price sensitive information.

Enquires:

 
 Creo Medical Group plc                                          investors.creomedical.com 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities plc                                                 [phone] 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne                    Mob: [phone] 
                                                                                   909 238 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by its unique full spectrum kamaptive technology to market, enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy Platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. An overview of the Creo Medical device technology portfolio can be seen here:

https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf

For more information about Creo Medical please see our website, www.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAFAPELDEFAA

(END) Dow Jones Newswires

December 09, 2020 02:00 ET (07:00 GMT)